BioNTech halted its Phase 2 trial for a colorectal cancer vaccine after a Data Safety Monitoring Board found no efficacy, causing its stock to fall 8%. This setback also pressured Moderna's shares, which dropped 6%, despite its recent melanoma vaccine success. Pfizer's stock remained mostly unaffected due to its diversified portfolio and recent FDA approval for a COVID-19 vaccine update. The failure highlights challenges for mRNA vaccines in treating immunotherapy-resistant tumors and prompts investors to reassess the potential of mRNA cancer therapies. Upcoming trial results and industry data may clarify the future outlook for these treatments.
BioNTech SE maintains a Strong Buy rating due to its promising late-stage oncology pipeline and strategic partnerships. Key drug candidates, gotistobart and pumitamig, have important trial data expected in 2026, supporting future growth. While the CO...
Moderna's stock jumped 11% with no new company news, driven by strong retail sentiment and trading momentum rather than fundamentals. Meanwhile, BioNTech rose only 2%, lagging behind both Moderna and the broader biotech sector, highlighting a growing...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
